English
SUMO is a peptide post-translational modifier, which is covalently conjugated to lysine side chains of thousands of proteins to regulate their function and fate. As such SUMOylation has been involved in the regulation of most cellular processes and its dysregulation associated with many pathologies (neurodegenerative diseases, metabolic disorders, viral infections, cancer...). However, very few molecules targeting SUMOylation have been identified so far. Our interdisciplinary project aims at developing stapled peptides able to inhibit the interaction between the SUMO E1 activating and E2 conjugating enzymes and thus prevent the transfer of SUMO on its targets. These peptides will also be used as “warheads” to create (i) PROTACs aiming at inducing the degradation of the E1 enzyme and (ii) photoinducible SUMOylation inhibitors. These new tools will be used to better understand the roles of SUMOylation and serve as basis to develop therapeutic molecules. In addition, the results obtained in the frame of this project will help develop strategies to target protein-protein interfaces, which are emerging as highly promising for the development of inhibitors. This project if based on an interdisciplinary consortium comprising 4 teams specialists of the biology of SUMOylation (IGMM, coordinator), chemistry of stapled peptides and PROTACs (IBMM), structural biology (CR2M) and biochemistry of SUMOylation (CR2M, Barcelona).
